XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.23.2

Segment reporting | 6 Months Ended
--- | ---
Jun. 30, 2023
Segment Reporting [Abstract] |
Segment Reporting Disclosure | Segment reporting The Company’s operating divisions are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. IKC business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support. The Company’s separate operating segments include its U.S. dialysis and related lab services business, its U.S. IKC business, its U.S. other ancillary services, its kidney care operations in each foreign sovereign jurisdiction, and its equity method investments in each of the Asia Pacific joint venture (APAC JV) and Mozarc. The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category. See Note 25 to the Company's consolidated financial statements included in the 2022 10-K for further description of how the Company determines and measures results for its operating segments. The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:
| Three months ended June 30, |  | Six months ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Segment revenues: |  |  |  |  |  |  |
U.S. dialysis |  |  |  |  |  |  |
Dialysis patient service revenues: |  |  |  |  |  |  |
External sources | $ | 2,703,850 |  |  | $ | 2,637,738 |  |  | $ | 5,287,782 |  |  | $ | 5,184,700 |
Intersegment revenues | 20,361 |  |  | 19,410 |  |  | 42,410 |  |  | 41,568 |
U.S. dialysis patient service revenues | 2,724,211 |  |  | 2,657,148 |  |  | 5,330,192 |  |  | 5,226,268 |
Other revenues: |  |  |  |  |  |  |
External sources | 6,404 |  |  | 6,113 |  |  | 12,583 |  |  | 12,078 |
Intersegment revenues | — |  |  | (21) |  |  | — |  |  | (10) |
Total U.S. dialysis revenues | 2,730,615 |  |  | 2,663,240 |  |  | 5,342,775 |  |  | 5,238,336 |
Other—Ancillary services |  |  |  |  |  |  |
Dialysis patient service revenues | 186,835 |  |  | 172,361 |  |  | 362,937 |  |  | 341,680 |
Other external sources | 103,280 |  |  | 110,545 |  |  | 209,766 |  |  | 205,854 |
Intersegment revenues | 1,408 |  |  | — |  |  | 2,774 |  |  | — |
Total ancillary services revenues | 291,523 |  |  | 282,906 |  |  | 575,477 |  |  | 547,534 |
Total net segment revenues | 3,022,138 |  |  | 2,946,146 |  |  | 5,918,252 |  |  | 5,785,870 |
Elimination of intersegment revenues | (21,769) |  |  | (19,389) |  |  | (45,184) |  |  | (41,558) |
Consolidated revenues | $ | 3,000,369 |  |  | $ | 2,926,757 |  |  | $ | 5,873,068 |  |  | $ | 5,744,312 |
Segment operating margin (loss): |  |  |  |  |  |  |
U.S. dialysis | $ | 460,759 |  |  | $ | 472,801 |  |  | $ | 821,857 |  |  | $ | 879,241 |
Other—Ancillary services | (21,604) |  |  | (9,113) |  |  | (46,469) |  |  | (41,418) |
Total segment operating margin | 439,155 |  |  | 463,688 |  |  | 775,388 |  |  | 837,823 |
Reconciliation of segment operating income to consolidated income before income taxes: |  |  |  |  |  |  |
Corporate administrative support | (33,864) |  |  | (30,973) |  |  | (58,452) |  |  | (66,800) |
Consolidated operating income | 405,291 |  |  | 432,715 |  |  | 716,936 |  |  | 771,023 |
Debt expense | (103,507) |  |  | (82,586) |  |  | (204,281) |  |  | (156,377) |
Debt prepayment and refinancing charges | (7,962) |  |  | — |  |  | (7,962) |  |  | — |
Other income (loss), net | 1,373 |  |  | (1,284) |  |  | 5,125 |  |  | (3,070) |
Consolidated income before income taxes | $ | 295,195 |  |  | $ | 348,845 |  |  | $ | 509,818 |  |  | $ | 611,576 |
Depreciation and amortization expense by reportable segment was as follows:
| Three months ended June 30, |  | Six months ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
U.S. dialysis | $ | 171,842 |  |  | $ | 160,612 |  |  | $ | 338,803 |  |  | $ | 322,632 |
Other—Ancillary services | 11,830 |  |  | 10,564 |  |  | 22,940 |  |  | 21,488 |
| $ | 183,672 |  |  | $ | 171,176 |  |  | $ | 361,743 |  |  | $ | 344,120 |
Expenditures for property and equipment by reportable segment were as follows:
|  |  | Six months ended June 30,
|  |  |  |  | 2023 |  | 2022
U.S. dialysis |  |  |  |  | $ | 240,474 |  |  | $ | 237,686 |
Other—Ancillary services |  |  |  |  | 31,730 |  |  | 27,775 |
|  |  |  |  | $ | 272,204 |  |  | $ | 265,461 |
A summary of assets by reportable segment were as follows:
| June 30, 2023 |  | December 31, 2022
U.S. dialysis | $ | 14,592,384 |  |  | $ | 15,084,454 |
Other—Ancillary services | 2,366,461 |  |  | 1,843,798 |
Consolidated assets | $ | 16,958,845 |  |  | $ | 16,928,252 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration